;PMID: 8627562
;source_file_874.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:51..128] = [t:51..128]
;2)section:[e:132..183] = [t:132..183]
;3)section:[e:187..299] = [t:187..299]
;4)sentence:[e:303..414] = [t:303..414]
;5)sentence:[e:415..572] = [t:415..572]
;6)sentence:[e:573..634] = [t:573..634]
;7)sentence:[e:635..771] = [t:635..771]
;8)sentence:[e:772..945] = [t:772..945]
;9)sentence:[e:946..1159] = [t:946..1159]
;10)sentence:[e:1160..1435] = [t:1160..1435]
;11)sentence:[e:1436..1725] = [t:1436..1725]
;12)sentence:[e:1726..1957] = [t:1726..1957]
;13)sentence:[e:1958..2165] = [t:1958..2165]
;14)sentence:[e:2167..2390] = [t:2167..2390]
;15)sentence:[e:2391..2482] = [t:2391..2482]
;16)section:[e:2486..2530] = [t:2486..2530]

;section 0 Span:0..45
;J Pharmacol Exp Ther. 1996 May;277(2):805-16.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (,:[20..21] .) (CD:[22..26] 1996) (NNP:[27..30] May)
        (CD:[30..35] ;277-LRB-) (CD:[35..36] 2) (-RRB-:[36..37] -RRB-)
        (CD:[37..41] :805) (::[41..42] -) (CD:[42..44] 16) (.:[44..45] .)))

;sentence 1 Span:51..128
;Identification of the human P450 enzymes involved in lansoprazole
;metabolism.
;[79..91]:cyp450:"P450 enzymes"
;[104..116]:substance:"lansoprazole"
(SENT
  (NP-HLN
    (NP (NN:[51..65] Identification))
    (PP (IN:[66..68] of)
      (NP
        (NP (DT:[69..72] the) (JJ:[73..78] human)
           (NN:[79..83] P450) (NNS:[84..91] enzymes))
        (VP (VBN:[92..100] involved)
          (NP (-NONE-:[100..100] *))
          (PP-CLR (IN:[101..103] in)
            (NP (NN:[104..116] lansoprazole) (NN:[117..127] metabolism))))))
    (.:[127..128] .)))

;section 2 Span:132..183
;Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A.
(SEC
  (FRAG (NNP:[132..138] Pearce) (NNP:[139..141] RE) (,:[141..142] ,)
        (NNP:[143..152] Rodrigues) (NNP:[153..155] AD) (,:[155..156] ,)
        (NNP:[157..166] Goldstein) (NNP:[167..169] JA) (,:[169..170] ,)
        (NNP:[171..180] Parkinson) (NN:[181..183] A.)))

;section 3 Span:187..299
;Department of Pharmacology, Toxicology and Therapeutics, University of Kansas
; Medical Center, Kansas City, USA.
(SEC
  (FRAG (NNP:[187..197] Department) (IN:[198..200] of)
        (NNP:[201..213] Pharmacology) (,:[213..214] ,)
        (NNP:[215..225] Toxicology) (CC:[226..229] and)
        (NNP:[230..242] Therapeutics) (,:[242..243] ,)
        (NNP:[244..254] University) (IN:[255..257] of) (NNP:[258..264] Kansas)
        (NNP:[266..273] Medical) (NNP:[274..280] Center) (,:[280..281] ,)
        (NNP:[282..288] Kansas) (NNP:[289..293] City) (,:[293..294] ,)
        (NNP:[295..298] USA) (.:[298..299] .)))

;sentence 4 Span:303..414
;The aim of this study was to identify which human P450 enzymes are involved
;in  the metabolism of lansoprazole.
;[353..365]:cyp450:"P450 enzymes"
;[401..413]:substance:"lansoprazole"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[303..306] The) (NN:[307..310] aim))
      (PP (IN:[311..313] of)
        (NP (DT:[314..318] this) (NN:[319..324] study))))
    (VP (VBD:[325..328] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[328..328] *))
        (VP (TO:[329..331] to)
          (VP (VB:[332..340] identify)
            (SBAR
              (WHNP-1 (WDT:[341..346] which) (JJ:[347..352] human)
                 (NN:[353..357] P450) (NNS:[358..365] enzymes))
              (S
                (NP-SBJ-1 (-NONE-:[365..365] *T*))
                (VP (VBP:[366..369] are)
                  (VP (VBN:[370..378] involved)
                    (NP-1 (-NONE-:[378..378] *))
                    (PP-CLR (IN:[379..381] in)
                      (NP
                        (NP (DT:[383..386] the) (NN:[387..397] metabolism))
                        (PP (IN:[398..400] of)
                          (NP (NN:[401..413] lansoprazole)))))))))))))
    (.:[413..414] .)))

;sentence 5 Span:415..572
;In the presence of NADPH and oxygen, human liver  microsomes converted
;lansoprazole to lansoprazole sulfide, lansoprazole sulfone  and
;5-hydroxylansoprazole.
;[434..439]:substance:"NADPH"
;[444..450]:substance:"oxygen"
;[486..498]:substance:"lansoprazole"
;[502..522]:substance:"lansoprazole sulfide"
;[524..544]:substance:"lansoprazole sulfone"
;[550..571]:substance:"5-hydroxylansoprazole"
(SENT
  (S
    (PP (IN:[415..417] In)
      (NP
        (NP (DT:[418..421] the) (NN:[422..430] presence))
        (PP (IN:[431..433] of)
          (NP (NN:[434..439] NADPH) (CC:[440..443] and) (NN:[444..450] oxygen)))))
    (,:[450..451] ,)
    (NP-SBJ (JJ:[452..457] human) (NN:[458..463] liver)
            (NNS:[465..475] microsomes))
    (VP (VBD:[476..485] converted)
      (NP (NN:[486..498] lansoprazole))
      (PP (TO:[499..501] to)
        (NP
          (NP (NN:[502..514] lansoprazole) (NN:[515..522] sulfide))
          (,:[522..523] ,)
          (NP (NN:[524..536] lansoprazole) (NN:[537..544] sulfone))
          (CC:[546..549] and)
          (NP (NN:[550..571] 5-hydroxylansoprazole)))))
    (.:[571..572] .)))

;sentence 6 Span:573..634
;Formation of lansoprazole sulfide occurred  nonenzymatically.
;[586..606]:substance:"lansoprazole sulfide"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[573..582] Formation))
      (PP (IN:[583..585] of)
        (NP (NN:[586..598] lansoprazole) (NN:[599..606] sulfide))))
    (VP (VBD:[607..615] occurred)
      (ADVP (RB:[617..633] nonenzymatically)))
    (.:[633..634] .)))

;sentence 7 Span:635..771
;The formation of lansoprazole sulfone appeared to be catalyzed  by a single,
;low-affinity enzyme (apparent Km approximately 100 microM).
;[652..672]:substance:"lansoprazole sulfone"
;[725..731]:substance:"enzyme"
;[742..744]:quantitative-name:"Km"
;[745..762]:quantitative-value:"approximately 100"
;[763..769]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[635..638] The) (NN:[639..648] formation))
      (PP (IN:[649..651] of)
        (NP (NN:[652..664] lansoprazole) (NN:[665..672] sulfone))))
    (VP (VBD:[673..681] appeared)
      (S
        (NP-SBJ-1 (-NONE-:[681..681] *))
        (VP (TO:[682..684] to)
          (VP (VB:[685..687] be)
            (VP (VBN:[688..697] catalyzed)
              (NP-1 (-NONE-:[697..697] *))
              (PP (IN:[699..701] by)
                (NP-LGS (DT:[702..703] a) (JJ:[704..710] single)
                        (,:[710..711] ,)
                  (ADJP (JJ:[712..715] low) (HYPH:[715..716] -)
                        (NN:[716..724] affinity))
                  (NN:[725..731] enzyme)
                  (PRN (-LRB-:[732..733] -LRB-)
                    (S
                      (NP-SBJ (JJ:[733..741] apparent) (NN:[742..744] Km))
                      (NP-PRD
                        (QP (RB:[745..758] approximately) (CD:[759..762] 100))
                        (NN:[763..769] microM)))
                    (-RRB-:[769..770] -RRB-)))))))))
    (.:[770..771] .)))

;sentence 8 Span:772..945
;In  contrast, lansoprazole 5-hydroxylation appeared to be catalyzed by two 
;kinetically distinct enzymes (apparent Km approximately 100 microM and 
;approximately 15 microM).
;[786..798]:substance:"lansoprazole"
;[869..876]:substance:"enzymes"
;[887..889]:quantitative-name:"Km"
;[890..907]:quantitative-value:"approximately 100"
;[908..914]:quantitative-units:"microM"
;[920..936]:quantitative-value:"approximately 15"
;[937..943]:quantitative-units:"microM"
(SENT
  (S
    (PP (IN:[772..774] In)
      (NP (NN:[776..784] contrast)))
    (,:[784..785] ,)
    (NP-SBJ-1 (NN:[786..798] lansoprazole) (NN:[799..814] 5-hydroxylation))
    (VP (VBD:[815..823] appeared)
      (S
        (NP-SBJ-1 (-NONE-:[823..823] *))
        (VP (TO:[824..826] to)
          (VP (VB:[827..829] be)
            (VP (VBN:[830..839] catalyzed)
              (NP-1 (-NONE-:[839..839] *))
              (PP (IN:[840..842] by)
                (NP-LGS (CD:[843..846] two)
                  (ADJP (RB:[848..859] kinetically) (JJ:[860..868] distinct))
                  (NNS:[869..876] enzymes)
                  (PRN (-LRB-:[877..878] -LRB-)
                    (S
                      (NP-SBJ (JJ:[878..886] apparent) (NN:[887..889] Km))
                      (NP-PRD
                        (NP
                          (QP (RB:[890..903] approximately) (CD:[904..907] 100))
                          (NN:[908..914] microM))
                        (CC:[915..918] and)
                        (NP
                          (QP (RB:[920..933] approximately) (CD:[934..936] 15))
                          (NN:[937..943] microM))))
                    (-RRB-:[943..944] -RRB-)))))))))
    (.:[944..945] .)))

;sentence 9 Span:946..1159
;When human liver microsomes (n = 16) were incubated  with 100 microM
;lansoprazole, both the 5-hydroxylation and sulfoxidation of  lansoprazole
;appeared to be catalyzed by CYP3A4/5 (based on correlation  analyses).
;[1004..1007]:quantitative-value:"100"
;[1008..1014]:quantitative-units:"microM"
;[1015..1027]:substance:"lansoprazole"
;[1076..1088]:substance:"lansoprazole"
;[1117..1123]:cyp450:"CYP3A4"
;[1117..1122]...[1124..1125]:cyp450:"CYP3A"..."5"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-2 (WRB:[946..950] When))
      (S
        (NP-SBJ-1 (JJ:[951..956] human) (NN:[957..962] liver)
                  (NNS:[963..973] microsomes)
          (PRN (-LRB-:[974..975] -LRB-)
            (S
              (NP-SBJ (NN:[975..976] n))
              (VP (SYM:[977..978] =)
                (NP (CD:[979..981] 16))))
            (-RRB-:[981..982] -RRB-)))
        (VP (VBD:[983..987] were)
          (VP (VBN:[988..997] incubated)
            (NP-1 (-NONE-:[997..997] *))
            (PP (IN:[999..1003] with)
              (NP
                (NML (CD:[1004..1007] 100) (NN:[1008..1014] microM))
                (NN:[1015..1027] lansoprazole)))
            (ADVP-TMP-2 (-NONE-:[1027..1027] *T*))))))
    (,:[1027..1028] ,)
    (NP-SBJ-4
      (NP (CC:[1029..1033] both) (DT:[1034..1037] the)
          (NN:[1038..1053] 5-hydroxylation) (CC:[1054..1057] and)
          (NN:[1058..1071] sulfoxidation))
      (PP (IN:[1072..1074] of)
        (NP (NN:[1076..1088] lansoprazole))))
    (VP (VBD:[1089..1097] appeared)
      (S
        (NP-SBJ-4 (-NONE-:[1097..1097] *))
        (VP (TO:[1098..1100] to)
          (VP (VB:[1101..1103] be)
            (VP (VBN:[1104..1113] catalyzed)
              (NP-4 (-NONE-:[1113..1113] *))
              (PP (IN:[1114..1116] by)
                (NP-LGS
                  (NP
                    (NML-3 (NN:[1117..1122] CYP3A))
                    (CD:[1122..1123] 4))
                  (SYM:[1123..1124] /)
                  (NP
                    (NML-3 (-NONE-:[1124..1124] *P*))
                    (CD:[1124..1125] 5))
                  (PRN (-LRB-:[1126..1127] -LRB-)
                    (VP (VBN:[1127..1132] based)
                      (NP (-NONE-:[1132..1132] *))
                      (PP-CLR (IN:[1133..1135] on)
                        (NP (NN:[1136..1147] correlation)
                            (NNS:[1149..1157] analyses))))
                    (-RRB-:[1157..1158] -RRB-)))))))))
    (.:[1158..1159] .)))

;sentence 10 Span:1160..1435
;Antibodies against rat CYP3A enzymes inhibited the rate of both 
;5-hydroxylation (approximately 55%) and sulfoxidation (approximately 70%) and
; cDNA-expressed CYP3A4 catalyzed both the 5-hydroxylation and sulfoxidation
;of  lansoprazole (apparent Km approximately 100 microM).
;[1160..1170]:substance:"Antibodies"
;[1183..1196]:cyp450:"CYP3A enzymes"
;[1242..1259]:quantitative-value:"approximately 55%"
;[1280..1297]:quantitative-value:"approximately 70%"
;[1304..1308]:substance:"cDNA"
;[1319..1325]:cyp450:"CYP3A4"
;[1383..1395]:substance:"lansoprazole"
;[1406..1408]:quantitative-name:"Km"
;[1409..1426]:quantitative-value:"approximately 100"
;[1427..1433]:quantitative-units:"microM"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NNS:[1160..1170] Antibodies))
        (PP (IN:[1171..1178] against)
          (NP (NN:[1179..1182] rat)
             (NN:[1183..1188] CYP3A) (NNS:[1189..1196] enzymes))))
      (VP (VBD:[1197..1206] inhibited)
        (NP
          (NP (DT:[1207..1210] the) (NN:[1211..1215] rate))
          (PP (IN:[1216..1218] of)
            (NP (CC:[1219..1223] both)
              (NP (NN:[1225..1240] 5-hydroxylation)
                (PRN (-LRB-:[1241..1242] -LRB-)
                  (NP
                    (QP (RB:[1242..1255] approximately) (CD:[1256..1258] 55))
                    (NN:[1258..1259] %))
                  (-RRB-:[1259..1260] -RRB-)))
              (CC:[1261..1264] and)
              (NP (NN:[1265..1278] sulfoxidation)
                (PRN (-LRB-:[1279..1280] -LRB-)
                  (NP
                    (QP (RB:[1280..1293] approximately) (CD:[1294..1296] 70))
                    (NN:[1296..1297] %))
                  (-RRB-:[1297..1298] -RRB-))))))))
    (CC:[1299..1302] and)
    (S
      (NP-SBJ
        (ADJP (NN:[1304..1308] cDNA) (HYPH:[1308..1309] -)
              (VBN:[1309..1318] expressed))
        (NN:[1319..1325] CYP3A4))
      (VP (VBD:[1326..1335] catalyzed)
        (NP
          (NP (CC:[1336..1340] both) (DT:[1341..1344] the)
              (NN:[1345..1360] 5-hydroxylation) (CC:[1361..1364] and)
              (NN:[1365..1378] sulfoxidation))
          (PP (IN:[1379..1381] of)
            (NP (NN:[1383..1395] lansoprazole)))
          (PRN (-LRB-:[1396..1397] -LRB-)
            (S
              (NP-SBJ (JJ:[1397..1405] apparent) (NN:[1406..1408] Km))
              (NP-PRD
                (ADJP (RB:[1409..1422] approximately) (CD:[1423..1426] 100))
                (NN:[1427..1433] microM)))
            (-RRB-:[1433..1434] -RRB-)))))
    (.:[1434..1435] .)))

;sentence 11 Span:1436..1725
;However, at the  pharmacologically relevant substrate concentration of 1
;microM, lansoprazole  sulfoxidation was still highly correlated with CYP3A4/5
;activity (r2 = .905),  but lansoprazole 5-hydroxylation appeared to be
;catalyzed by CYP2C19 (r2 = .875)  rather than CYP3A4/5 (r2 = .113).
;[1480..1489]:substance:"substrate"
;[1507..1508]:quantitative-value:"1"
;[1509..1515]:quantitative-units:"microM"
;[1517..1529]:substance:"lansoprazole"
;[1578..1584]:cyp450:"CYP3A4"
;[1578..1583]...[1585..1586]:cyp450:"CYP3A"..."5"
;[1614..1626]:substance:"lansoprazole"
;[1671..1678]:cyp450:"CYP2C19"
;[1704..1710]:cyp450:"CYP3A4"
;[1704..1709]...[1711..1712]:cyp450:"CYP3A"..."5"
(SENT
  (S
    (S
      (ADVP (RB:[1436..1443] However))
      (,:[1443..1444] ,)
      (PP (IN:[1445..1447] at)
        (NP
          (NP (DT:[1448..1451] the)
            (ADJP (RB:[1453..1470] pharmacologically) (JJ:[1471..1479] relevant))
            (NN:[1480..1489] substrate) (NN:[1490..1503] concentration))
          (PP (IN:[1504..1506] of)
            (NP (CD:[1507..1508] 1) (NN:[1509..1515] microM)))))
      (,:[1515..1516] ,)
      (NP-SBJ-3 (NN:[1517..1529] lansoprazole) (NN:[1531..1544] sulfoxidation))
      (VP (VBD:[1545..1548] was)
        (ADVP (RB:[1549..1554] still))
        (ADVP (RB:[1555..1561] highly))
        (VP (VBN:[1562..1572] correlated)
          (NP-3 (-NONE-:[1572..1572] *))
          (PP-CLR (IN:[1573..1577] with)
            (NP
              (NP
                
                (NML-1 (NN:[1578..1583] CYP3A))
                (CD:[1583..1584] 4)
                (NML-2 (-NONE-:[1584..1584] *P*)))
              (SYM:[1584..1585] /)
              (NP
                (NML-1 (-NONE-:[1585..1585] *P*))
                (CD:[1585..1586] 5)
                (NML-2 (NN:[1587..1595] activity)))
              (PRN (-LRB-:[1596..1597] -LRB-)
                (S
                  (NP-SBJ (NN:[1597..1599] r2))
                  (VP (SYM:[1600..1601] =)
                    (NP (CD:[1602..1606] .905))))
                (-RRB-:[1606..1607] -RRB-)))))))
    (,:[1607..1608] ,) (CC:[1610..1613] but)
    (S
      (NP-SBJ-5 (NN:[1614..1626] lansoprazole) (NN:[1627..1642] 5-hydroxylation))
      (VP (VBD:[1643..1651] appeared)
        (S
          (NP-SBJ-5 (-NONE-:[1651..1651] *))
          (VP (TO:[1652..1654] to)
            (VP (VB:[1655..1657] be)
              (VP (VBN:[1658..1667] catalyzed)
                (NP-5 (-NONE-:[1667..1667] *))
                (PP (IN:[1668..1670] by)
                  (NP-LGS
                    (NP (NN:[1671..1678] CYP2C19)
                      (PRN (-LRB-:[1679..1680] -LRB-)
                        (S
                          (NP-SBJ (NN:[1680..1682] r2))
                          (VP (SYM:[1683..1684] =)
                            (NP-PRD (CD:[1685..1689] .875))))
                        (-RRB-:[1689..1690] -RRB-)))
                    (PP (IN:[1692..1698] rather) (IN:[1699..1703] than)
                      (NP
                        (NP
                          (NML-4 (NN:[1704..1709] CYP3A))
                          (CD:[1709..1710] 4))
                        (SYM:[1710..1711] /)
                        (NP
                          (NML-4 (-NONE-:[1711..1711] *P*))
                          (CD:[1711..1712] 5))
                        (PRN (-LRB-:[1713..1714] -LRB-)
                          (S
                            (NP-SBJ (NN:[1714..1716] r2))
                            (VP (SYM:[1717..1718] =)
                              (NP (CD:[1719..1723] .113))))
                          (-RRB-:[1723..1724] -RRB-))))))))))))
    (.:[1724..1725] .)))

;sentence 12 Span:1726..1957
;Antibodies and chemical inhibitors of CYP2C  enzymes preferentially inhibited
;the 5-hydroxylation of lansoprazole, whereas  lansoprazole sulfoxidation was
;preferentially inhibited by antibodies and  chemical inhibitors of CYP3A4/5.
;[1726..1736]:substance:"Antibodies"
;[1741..1760]:substance:"chemical inhibitors"
;[1764..1778]:cyp450:"CYP2C  enzymes"
;[1827..1839]:substance:"lansoprazole"
;[1850..1862]:substance:"lansoprazole"
;[1909..1919]:substance:"antibodies"
;[1925..1944]:substance:"chemical inhibitors"
;[1948..1954]:cyp450:"CYP3A4"
;[1948..1953]...[1955..1956]:cyp450:"CYP3A"..."5"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NNS:[1726..1736] Antibodies))
        (CC:[1737..1740] and)
        (NP (JJ:[1741..1749] chemical) (NNS:[1750..1760] inhibitors)))
      (PP (IN:[1761..1763] of)
        (NP (NN:[1764..1769] CYP2C) (NNS:[1771..1778] enzymes))))
    (ADVP (RB:[1779..1793] preferentially))
    (VP (VBD:[1794..1803] inhibited)
      (NP
        (NP (DT:[1804..1807] the) (NN:[1808..1823] 5-hydroxylation))
        (PP (IN:[1824..1826] of)
          (NP (NN:[1827..1839] lansoprazole))))
      (,:[1839..1840] ,)
      (SBAR-ADV (IN:[1841..1848] whereas)
        (S
          (NP-SBJ-2 (NN:[1850..1862] lansoprazole)
                    (NN:[1863..1876] sulfoxidation))
          (VP (VBD:[1877..1880] was)
            (ADVP (RB:[1881..1895] preferentially))
            (VP (VBN:[1896..1905] inhibited)
              (NP-2 (-NONE-:[1905..1905] *))
              (PP (IN:[1906..1908] by)
                (NP-LGS
                  (NP
                    (NP (NNS:[1909..1919] antibodies))
                    (CC:[1920..1923] and)
                    (NP (JJ:[1925..1933] chemical) (NNS:[1934..1944] inhibitors)))
                  (PP (IN:[1945..1947] of)
                    (NP
                      (NP
                        (NML-1 (NN:[1948..1953] CYP3A))
                        (CD:[1953..1954] 4))
                      (SYM:[1954..1955] /)
                      (NP
                        (NML-1 (-NONE-:[1955..1955] *P*))
                        (CD:[1955..1956] 5)))))))))))
    (.:[1956..1957] .)))

;sentence 13 Span:1958..2165
;The cDNA expressed enzymes CYP2C8, CYP2C9 and  CYP2C19 catalyzed varying
;rates of lansoprazole 5-hydroxylation at a substrate  concentration of 50
;microM, but only CYPC19 catalyzed this reaction at 1 microM.
;[1962..1966]:substance:"cDNA"
;[1977..1984]:cyp450:"enzymes"
;[1985..1991]:cyp450:"CYP2C8"
;[1993..1999]:cyp450:"CYP2C9"
;[2005..2012]:cyp450:"CYP2C19"
;[2040..2052]:substance:"lansoprazole"
;[2074..2083]:substance:"substrate"
;[2102..2104]:quantitative-value:"50"
;[2105..2111]:quantitative-units:"microM"
;[2122..2128]:cyp450:"CYPC19"
;[2156..2157]:quantitative-value:"1"
;[2158..2164]:quantitative-units:"microM"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1958..1961] The)
          (ADJP (NN:[1962..1966] cDNA) (VBN:[1967..1976] expressed))
          (NNS:[1977..1984] enzymes))
        (NP (NN:[1985..1991] CYP2C8) (,:[1991..1992] ,) (NN:[1993..1999] CYP2C9)
            (CC:[2000..2003] and) (NN:[2005..2012] CYP2C19)))
      (VP (VBD:[2013..2022] catalyzed)
        (NP
          (NP (VBG:[2023..2030] varying) (NNS:[2031..2036] rates))
          (PP (IN:[2037..2039] of)
            (NP (NN:[2040..2052] lansoprazole) (NN:[2053..2068] 5-hydroxylation))))
        (PP (IN:[2069..2071] at)
          (NP
            (NP (DT:[2072..2073] a) (NN:[2074..2083] substrate)
                (NN:[2085..2098] concentration))
            (PP (IN:[2099..2101] of)
              (NP (CD:[2102..2104] 50) (NN:[2105..2111] microM)))))))
    (,:[2111..2112] ,) (CC:[2113..2116] but)
    (S
      (NP-SBJ (RB:[2117..2121] only) (NN:[2122..2128] CYPC19))
      (VP (VBD:[2129..2138] catalyzed)
        (NP (DT:[2139..2143] this) (NN:[2144..2152] reaction))
        (PP (IN:[2153..2155] at)
          (NP (CD:[2156..2157] 1) (NN:[2158..2164] microM)))))
    (.:[2164..2165] .)))

;sentence 14 Span:2167..2390
;These results suggest that at pharmacologically relevant concentrations, the 
;5-hydroxylation of lansoprazole is primarily catalyzed by CYP2C19, whereas
;the  sulfoxidation of lansoprazole is primarily catalyzed by CYP3A4/5.
;[2264..2276]:substance:"lansoprazole"
;[2303..2310]:cyp450:"CYP2C19"
;[2342..2354]:substance:"lansoprazole"
;[2381..2387]:cyp450:"CYP3A4"
;[2381..2386]...[2388..2389]:cyp450:"CYP3A"..."5"
(SENT
  (S
    (NP-SBJ (DT:[2167..2172] These) (NNS:[2173..2180] results))
    (VP (VBP:[2181..2188] suggest)
      (SBAR (IN:[2189..2193] that)
        (S
          (PP (IN:[2194..2196] at)
            (NP
              (ADJP (RB:[2197..2214] pharmacologically)
                    (JJ:[2215..2223] relevant))
              (NNS:[2224..2238] concentrations)))
          (,:[2238..2239] ,)
          (NP-SBJ-1
            (NP (DT:[2240..2243] the) (NN:[2245..2260] 5-hydroxylation))
            (PP (IN:[2261..2263] of)
              (NP (NN:[2264..2276] lansoprazole))))
          (VP (VBZ:[2277..2279] is)
            (ADVP (RB:[2280..2289] primarily))
            (VP (VBN:[2290..2299] catalyzed)
              (NP-1 (-NONE-:[2299..2299] *))
              (PP (IN:[2300..2302] by)
                (NP-LGS (NN:[2303..2310] CYP2C19)))
              (,:[2310..2311] ,)
              (SBAR-ADV (IN:[2312..2319] whereas)
                (S
                  (NP-SBJ-3
                    (NP (DT:[2320..2323] the) (NN:[2325..2338] sulfoxidation))
                    (PP (IN:[2339..2341] of)
                      (NP (NN:[2342..2354] lansoprazole))))
                  (VP (VBZ:[2355..2357] is)
                    (ADVP (RB:[2358..2367] primarily))
                    (VP (VBN:[2368..2377] catalyzed)
                      (NP-3 (-NONE-:[2377..2377] *))
                      (PP (IN:[2378..2380] by)
                        (NP-LGS
                          (NP
                            (NML-2 (NN:[2381..2386] CYP3A))
                            (CD:[2386..2387] 4))
                          (SYM:[2387..2388] /)
                          (NP
                            (NML-2 (-NONE-:[2388..2388] *P*))
                            (CD:[2388..2389] 5)))))))))))))
    (.:[2389..2390] .)))

;sentence 15 Span:2391..2482
;It is possible  that individuals lacking CYP2C19 will be poor metabolizers of
;lansoprazole.
;[2432..2439]:cyp450:"CYP2C19"
;[2453..2465]:substance:"metabolizers"
;[2469..2481]:substance:"lansoprazole"
(SENT
  (S
    (NP-SBJ
      (NP (PRP:[2391..2393] It))
      (SBAR-1 (-NONE-:[2393..2393] *EXP*)))
    (VP (VBZ:[2394..2396] is)
      (ADJP-PRD (JJ:[2397..2405] possible)
        (SBAR-1 (IN:[2407..2411] that)
          (S
            (NP-SBJ
              (NP (NNS:[2412..2423] individuals))
              (VP (VBG:[2424..2431] lacking)
                (NP (NN:[2432..2439] CYP2C19))))
            (VP (MD:[2440..2444] will)
              (VP (VB:[2445..2447] be)
                (NP-PRD
                  (NP (JJ:[2448..2452] poor) (NNS:[2453..2465] metabolizers))
                  (PP (IN:[2466..2468] of)
                    (NP (NN:[2469..2481] lansoprazole))))))))))
    (.:[2481..2482] .)))

;section 16 Span:2486..2530
;PMID: 8627562 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2486..2490] PMID) (::[2490..2491] :) (CD:[2492..2499] 8627562)
        (NN:[2500..2501] -LSB-) (NNP:[2501..2507] PubMed) (::[2508..2509] -)
        (NN:[2510..2517] indexed) (IN:[2518..2521] for)
        (NNP:[2522..2530] MEDLINE-RSB-)))
